相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
Per Pfeiffer et al.
LANCET ONCOLOGY (2020)
PCN40 A SYSTEMATIC REVIEW AND EXPLORATORY NETWORK META-ANALYSIS OF THIRD-LINE TREATMENTS FOR METASTATIC COLORECTAL CANCER
T. Walter et al.
VALUE IN HEALTH (2020)
Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
Fen Wang et al.
SCIENTIFIC REPORTS (2020)
Comprehensive review of targeted therapy for colorectal cancer
Yuan-Hong Xie et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
Xiaofeng Chen et al.
ONCOLOGIST (2019)
Apatinib as an optional treatment in metastatic colorectal cancer
Aiyi Li et al.
MEDICINE (2019)
CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p
Jun Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer
Lijun Liang et al.
CLINICAL COLORECTAL CANCER (2018)
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial
Jin Li et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
Miaomiao Gou et al.
SCIENTIFIC REPORTS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
Chun-Yan Lan et al.
LANCET ONCOLOGY (2018)
Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy
Zui Liu et al.
THORACIC CANCER (2018)
The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
Dantong Sun et al.
ONCOTARGETS AND THERAPY (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Novel anti-angiogenic therapeutic strategies in colorectal cancer
M. Tampellini et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
Frede Donskov et al.
BRITISH JOURNAL OF CANCER (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer
Xichun Hu et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy J. Price et al.
LANCET ONCOLOGY (2014)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
Yasuhide Yamada et al.
LANCET ONCOLOGY (2013)
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
Yong Sang Hong et al.
LANCET ONCOLOGY (2012)
Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
Jin Li et al.
BMC CANCER (2010)
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro et al.
LANCET ONCOLOGY (2010)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
H-C Jeung et al.
BRITISH JOURNAL OF CANCER (2006)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
